Cibus, Inc.
NASDAQ:CBUSBiotechnology
+$0.04 today
- Market cap
- $104.71M
- Beta
- 1.65
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.16
Volume 0.25M
Average 0.51M
CBUS Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Cibus, Inc.NASDAQ: CBUS
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items declines year over year
Q1 FY2026 other non-cash items of $9.13M fell 68.5% year over year, ahead of the -79.4% change in trailing-twelve-month other non-cash items. Sequentially, it fell 50.7% from the prior quarter.
Context
- Other non-cash items amounted to 1650.5% of revenue in FY2025, down 3198.8 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -68.5% holds above the trailing-twelve-month pace of -79.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 60.06M USD
- Year-over-year change
- -70.9%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.06M | -70.9% |
| FY2024 | 2024-12-31 | 206.68M | -4.2% |
| FY2023 | 2023-12-31 | 215.76M | +4314.1% |
| FY2022 | 2022-12-31 | (5.12M) | -235.1% |
| FY2021 | 2021-12-31 | (1.53M) | — |
Other Non-Cash Items vs competitors
How CBUS compares with its peers on the latest reported figures
- CBUS's LTM Mar 2026 other non-cash items of $46.54M is the largest of the 10 companies compared; the peer median is $595K.
- Its year-over-year change of -79.4% is the 8th highest of 10, against a peer median of +331.5%.
- Other non-cash items amounts to 1085.8% of revenue for CBUS, versus a peer median of 146.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CBUSCibus, Inc. | LTM Mar 2026 | $46.54M | -79.4% | — | 1085.8% |
| LTM Mar 2026 | $39.12M | +2806.7% | — | 994.5% | |
| LTM Mar 2026 | $12.57M | -582.5% | — | — | |
| LTM Mar 2026 | $11.87M | +180.6% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.27M | +14.2% | +214.5% | — |
| LTM Mar 2026 | $3.61M | +627.4% | — | — | |
| LTM Mar 2026 | $952K | -137.7% | -20.3% | 0.4% | |
| LTM Mar 2026 | $873.86K | +415.7% | +2.1% | 146.5% | |
| LTM Mar 2026 | $595K | +331.5% | -76.4% | — | |
| LTM Mar 2026 | $371K | +396.8% | — | — | |
| Peer median (excluding CBUS) | $595K | +331.5% | -9.1% | 146.5% | |
Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29.2M) | (16.89M) | (267.63M) | (282.71M) | (127.09M) |
| Depreciation & Amortization | 2.34M | 1.53M | 4.69M | 6.86M | 5.92M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.09M | 4M | 16.09M | 10.75M | 8.19M |
| Change in Working Capital | 7.49M | (2.89M) | 961K | 383K | 2.32M |
| Accounts Receivables | 4.89M | 0 | 1.7M | (512K) | 538K |
| Inventory | 1.38M | 0 | 0 | 0 | 0 |
| Accounts Payables | (360K) | (229K) | 2K | (188K) | 720K |
| Other Working Capital | 1.58M | (2.66M) | (745K) | 1.08M | 1.06M |
| Other Non-Cash Items | (1.53M) | (5.12M) | 215.76M | 206.68M | 60.06M |
| Operating Cash Flow | (18.81M) | (19.36M) | (46.21M) | (58.04M) | (50.59M) |
| Capital Expenditures | (497K) | (1.52M) | (4.32M) | (808K) | (578K) |
| Acquisitions (Net) | 0 | 0 | 59.38M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 11.7M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 11.2M | (1.52M) | 55.06M | (808K) | (578K) |
| Debt Repayment | (364K) | (376K) | (194K) | (879K) | (1.11M) |
| Common Stock Issued | 4.38M | 11.54M | 18.76M | 43.9M | 47.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (274K) | (1.17M) | 1.76M | (2.43M) | (142K) |
| Financing Cash Flow | 3.74M | 9.99M | 20.32M | 40.6M | 46.65M |
| Effect of Forex Changes | 498K | 99K | 3K | (13K) | 11K |
| Net Change in Cash | (3.87M) | (10.9M) | 29.17M | (18.27M) | (4.51M) |
| Free Cash Flow | (19.31M) | (20.88M) | (50.53M) | (58.85M) | (51.17M) |
Cibus, Inc.
NASDAQ:CBUS
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.